Human TRAIL R3/TNFRSF10C Antibody | R&D Systems MAB6302 product information

product summary

company name :

R&D Systems

product type :

antibody

product name :

Human TRAIL R3/TNFRSF10C Antibody

catalog :

MAB6302

quantity :

500 ug (also 25 ug)

price :

559 USD

clonality :

monoclonal

host :

mouse

conjugate :

nonconjugated

clone name :

90906

reactivity :

human

application :

flow cytometry

more info or order :

R&D Systems product webpage

citations: 15

Published Application/Species/Sample/Dilution	Reference
flow cytometry; human	Moniri M, Sun X, Rayat J, Dai D, Ao Z, He Z, et al. TRAIL-engineered pancreas-derived mesenchymal stem cells: characterization and cytotoxic effects on pancreatic cancer cells. Cancer Gene Ther. 2012;19:652-8 pubmed publisher
flow cytometry; human; 5 ug/ml	Moriwaki K, Shinzaki S, Miyoshi E. GDP-mannose-4,6-dehydratase (GMDS) deficiency renders colon cancer cells resistant to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor- and CD95-mediated apoptosis by inhibiting complex II formation. J Biol Chem. 2011;286:43123-33 pubmed publisher
flow cytometry; human	Zauli G, Rimondi E, Celeghini C, Milani D, Secchiero P. Dexamethasone counteracts the anti-osteoclastic, but not the anti-leukemic, activity of TNF-related apoptosis inducing ligand (TRAIL). J Cell Physiol. 2010;222:357-64 pubmed publisher
flow cytometry; human	Stary G, Klein I, Kohlhofer S, Koszik F, Scherzer T, Müllauer L, et al. Plasmacytoid dendritic cells express TRAIL and induce CD4+ T-cell apoptosis in HIV-1 viremic patients. Blood. 2009;114:3854-63 pubmed publisher
flow cytometry; human	Toscano F, Fajoui Z, Gay F, Lalaoui N, Parmentier B, Chayvialle J, et al. P53-mediated upregulation of DcR1 impairs oxaliplatin/TRAIL-induced synergistic anti-tumour potential in colon cancer cells. Oncogene. 2008;27:4161-71 pubmed publisher
flow cytometry; human	Weinmann L, Wischhusen J, Demma M, Naumann U, Roth P, Dasmahapatra B, et al. A novel p53 rescue compound induces p53-dependent growth arrest and sensitises glioma cells to Apo2L/TRAIL-induced apoptosis. Cell Death Differ. 2008;15:718-29 pubmed publisher
flow cytometry; human	Barbarotto E, Corallini F, Rimondi E, Fadda R, Mischiati C, Grill V, et al. Differential effects of chemotherapeutic drugs versus the MDM-2 antagonist nutlin-3 on cell cycle progression and induction of apoptosis in SKW6.4 lymphoblastoid B-cells. J Cell Biochem. 2008;104:595-605 pubmed
	Krishna Moorthy N, Seifert O, Eisler S, Weirich S, Kontermann R, Rehm M, et al. Low-Level Endothelial TRAIL-Receptor Expression Obstructs the CNS-Delivery of Angiopep-2 Functionalised TRAIL-Receptor Agonists for the Treatment of Glioblastoma. Molecules. 2021;26: pubmed publisher
	Yoo J, Bae S, Seo J, Jeon I, Vadevoo S, Kim S, et al. Designed ferritin nanocages displaying trimeric TRAIL and tumor-targeting peptides confer superior anti-tumor efficacy. Sci Rep. 2020;10:19997 pubmed publisher
	Neumann S, Hasenauer J, Pollak N, Scheurich P. Dominant negative effects of tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 4 on TRAIL receptor 1 signaling by formation of heteromeric complexes. J Biol Chem. 2014;289:16576-87 pubmed publisher
	Tang X, Lu J, Tu H, Huang K, Fu R, Cao G, et al. TRAIL-engineered bone marrow-derived mesenchymal stem cells: TRAIL expression and cytotoxic effects on C6 glioma cells. Anticancer Res. 2014;34:729-34 pubmed
	Shankar S, Chen Q, Ganapathy S, Singh K, Srivastava R. Diallyl trisulfide increases the effectiveness of TRAIL and inhibits prostate cancer growth in an orthotopic model: molecular mechanisms. Mol Cancer Ther. 2008;7:2328-38 pubmed publisher
	Locklin R, Federici E, Espina B, Hulley P, Russell R, Edwards C. Selective targeting of death receptor 5 circumvents resistance of MG-63 osteosarcoma cells to TRAIL-induced apoptosis. Mol Cancer Ther. 2007;6:3219-28 pubmed
	Braun F, Fecker L, Schwarz C, Walden P, Assaf C, Dürkop H, et al. Blockade of death receptor-mediated pathways early in the signaling cascade coincides with distinct apoptosis resistance in cutaneous T-cell lymphoma cells. J Invest Dermatol. 2007;127:2425-37 pubmed
	Singh T, Shankar S, Srivastava R. HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma. Oncogene. 2005;24:4609-23 pubmed

product information

master code :

MAB6302

SKU :

MAB6302

product name :

Human TRAIL R3/TNFRSF10C Antibody

unit size :

500 ug (also 25 ug)

description :

The Human TRAIL R3/TNFRSF10C Antibody from R&D Systems is a mouse monoclonal antibody to TRAILR3/TNFRSF10C. This antibody reacts with human,rat. The Human TRAIL R3/TNFRSF10C Antibody has been validated for the following applications: Flow Cytometry,CyTOF-ready.

target :

TRAIL R3/TNFRSF10C

category :

Primary Antibodies

buffer :

Lyophilized from a 0.2 ╡m filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 ╡m filtered solution in PBS.

clonality :

Monoclonal

clone :

90906

conjugate :

Unconjugated

host :

Mouse

immunogen :

Mouse myeloma cell line NS0-derived recombinant human TRAIL R3/TNFRSF10C, Met1-Ala221, Accession # O14798

isotype :

IgG1

purity :

Protein A or G purified from hybridoma culture supernatant

species :

Human,Rat

specificity :

Detects human TRAIL R3/TNFRSF10C in direct ELISAs and Western blots. In direct ELISAs and Western blots, no cross-reactivity with recombinant human (rh) TRAIL R2, rhTRAIL R1, or rhTRAIL R4 is observed.

gene symbol :

TNFRSF10C

top caption :

Detection of TRAIL R3/TNFRSF10C antibody in Human Blood Granulocytes antibody by Flow Cytometry.

accessionNumbers :

O14798

applications :

Flow Cytometry,CyTOF-ready

USD :

559 USD

alt names :

Antagonist decoy receptor for TRAIL/Apo-2L, CD263, CD263 antigen, cytotoxic TRAIL receptor-3, DcR1, DCR1MGC149502, Decoy receptor 1, Decoy TRAIL receptor without death domain, LITMGC149501, Lymphocyte inhibitor of TRAIL, TNFRSF10C, TRAIL receptor 3, TRAIL receptor without an intracellular domain, TRAILR3, TRAIL-R3, TRAILR3TNF-related apoptosis-inducing ligand receptor 3, TRIDDCR1-TNFR, tumor necrosis factor receptor superfamily member 10C, tumor necrosis factor receptor superfamily, member 10c, decoy without anintracellular domain

storage :

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 ░C as supplied. 1 month, 2 to 8 ░C under sterile conditions after reconstitution. 6 months, -20 to -70 ░C under sterile conditions after reconstitution.

more info or order :

R&D Systems product webpage